Patents by Inventor Randy Gastwirt

Randy Gastwirt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220025054
    Abstract: There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers.
    Type: Application
    Filed: July 29, 2021
    Publication date: January 27, 2022
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Randy Gastwirt, Heyue Zhou, John Dixon Gray, Guodi Lu
  • Publication number: 20220002422
    Abstract: There is disclosed compositions and methods relating to or derived from anti-c-Met antibodies. More specifically, there is disclosed fully human antibodies that bind c-Met, c-Met-binding fragments and derivatives of such antibodies, and c-Met-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having c-Met related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Application
    Filed: September 22, 2021
    Publication date: January 6, 2022
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Barbara A. Swanson, Heyue Zhou, Yan-Liang Zhang, Randy Gastwirt, John Dixon Gray
  • Publication number: 20210330787
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Application
    Filed: May 3, 2021
    Publication date: October 28, 2021
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann
  • Patent number: 11155628
    Abstract: There is disclosed compositions and methods relating to or derived from anti-c-Met antibodies. More specifically, there is disclosed fully human antibodies that bind c-Met, c-Met-binding fragments and derivatives of such antibodies, and c-Met-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having c-Met related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: October 26, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Barbara A. Swanson, Heyue Zhou, Yan-Liang Zhang, Randy Gastwirt, John Dixon Gray
  • Patent number: 11111304
    Abstract: There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: September 7, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Randy Gastwirt, Heyue Zhou, John Dixon Gray, Guodi Lu
  • Patent number: 11027012
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: June 8, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann
  • Patent number: 10717779
    Abstract: There is disclosed compositions and methods relating to or derived from anti-DLL-4 antibodies. More specifically, there is disclosed fully human antibodies that bind DLL-4, DLL-4-binding fragments and derivatives of such antibodies, and DLL-4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having DLL-4 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: July 21, 2020
    Assignee: Sorrento Therapeutics
    Inventors: Edwige Gros, Yanliang Zhang, Heyue Zhou, Randy Gastwirt
  • Patent number: 10519245
    Abstract: There is disclosed compositions and methods relating to or derived from anti-IGF1R antibodies. More specifically, there is disclosed fully human antibodies that bind IGF1R, IGF1R-binding fragments and derivatives of such antibodies, and IGF1R-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF1R related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: December 31, 2019
    Assignee: Sorrento Therapeutics Inc.
    Inventors: Randy Gastwirt, Heyue Zhou, Guodi Lu
  • Publication number: 20190359719
    Abstract: There is disclosed compositions and methods relating to or derived from anti-c-Met antibodies. More specifically, there is disclosed fully human antibodies that bind c-Met, c-Met-binding fragments and derivatives of such antibodies, and c-Met-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having c-Met related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Application
    Filed: June 25, 2019
    Publication date: November 28, 2019
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Barbara A. Swanson, Heyue Zhou, Yan-Liang Zhang, Randy Gastwirt, John Dixon Gray
  • Patent number: 10377827
    Abstract: There is disclosed compositions and methods relating to or derived from anti-c-Met antibodies. More specifically, there is disclosed fully human antibodies that bind c-Met, c-Met-binding fragments and derivatives of such antibodies, and c-Met-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having c-Met related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: August 13, 2019
    Assignee: SORRENTO THERAPEUTICS, INC.
    Inventors: Barbara A. Swanson, Heyue Zhou, Yan-Liang Zhang, Randy Gastwirt, John Dixon Gray
  • Publication number: 20190169282
    Abstract: There is disclosed compositions and methods relating to or derived from anti-DLL-4 antibodies. More specifically, there is disclosed fully human antibodies that bind DLL-4, DLL-4-binding fragments and derivatives of such antibodies, and DLL-4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having DLL-4 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Application
    Filed: January 7, 2019
    Publication date: June 6, 2019
    Inventors: Edwige GROS, Yanliang ZHANG, Heyue ZHOU, Randy GASTWIRT
  • Publication number: 20190060451
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Application
    Filed: August 24, 2018
    Publication date: February 28, 2019
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann
  • Publication number: 20190048087
    Abstract: There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers.
    Type: Application
    Filed: April 7, 2015
    Publication date: February 14, 2019
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Randy Gastwirt, Heyue Zhou, John Dixon Gray, Guodi Lu
  • Patent number: 10174107
    Abstract: There is disclosed compositions and methods relating to or derived from anti-DLL-4 antibodies. More specifically, there is disclosed fully human antibodies that bind DLL-4, DLL-4-binding fragments and derivatives of such antibodies, and DLL-4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having DLL-4 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: January 8, 2019
    Assignee: SORRENTO THERAPEUTICS, INC.
    Inventors: Edwige Gros, Yanliang Zhang, Heyue Zhou, Randy Gastwirt
  • Patent number: 10058609
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: August 28, 2018
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann
  • Patent number: 9944707
    Abstract: There is disclosed compositions and methods relating to or derived from anti-EGFR antibodies. More specifically, there is disclosed fully human antibodies that bind EGFR, EGFR-binding fragments and derivatives of such antibodies, and EGFR-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having EGFR-related disorders or conditions.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: April 17, 2018
    Assignee: SORRENTO THERAPEUTICS, INC.
    Inventors: Heyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray
  • Publication number: 20170283501
    Abstract: There is disclosed compositions and methods relating to or derived from anti-c-Met antibodies. More specifically, there is disclosed fully human antibodies that bind c-Met, c-Met-binding fragments and derivatives of such antibodies, and c-Met-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having c-Met related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Application
    Filed: June 21, 2013
    Publication date: October 5, 2017
    Inventors: Barbara A. Swanson, Heyue Zhou, Yan-Liang Zhang, Randy Gastwirt, John Dixon Gray
  • Publication number: 20170281765
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Application
    Filed: June 9, 2017
    Publication date: October 5, 2017
    Inventors: Heyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann
  • Publication number: 20170182161
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Application
    Filed: September 24, 2015
    Publication date: June 29, 2017
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann
  • Publication number: 20170166644
    Abstract: There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers.
    Type: Application
    Filed: April 7, 2015
    Publication date: June 15, 2017
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Randy Gastwirt, Heyue Zhou, John Dixon Gray, Guodi Lu